V2 receptor antagonists in cystic kidney diseases: An exciting step towards a practical treatment

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 838-839

  Bennett, William M ^a,b  

^a Northwest Renal Clinic   (United States)

^b LEGACY GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAFFEINE; CYCLIC AMP; DIURETIC AGENT; MOZAVAPTAN; PLACEBO; TOLVAPTAN; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG INHIBITION; EDITORIAL; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HUMAN; HYPONATREMIA; KIDNEY POLYCYSTIC DISEASE; NEPHRONOPHTHISIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; THIRST; TREATMENT OUTCOME; ANIMAL; DRUG ANTAGONISM; NOTE;

ANIMALS; BENZAZEPINES; HUMANS; KIDNEY DISEASES, CYSTIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; RECEPTORS, VASOPRESSIN;

EID: 24344433249     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005020136     Document Type: Editorial

References (9)

1. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PKC rat. J Am Soc Nephrol 16: 846-851, 2005
2. Torres VE: Cyclic AMP, at the hub of the cystic cycle. Kidney Int 66: 1283-1285, 2004
3. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM, Grantham JJ: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004
4. Guay-Woodford LM: Murine models of polycystic kidney disease: molecular and therapeutic insights. Am J Physiol Renal Physiol 285: F1034-F1049, 2003
5. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
6. Gattone VH, Wang X, Harris PC, Torres VH: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
7. Ohnishi A, Orita Y, Takagi N, Fujita T, Toyoki T, Ihara Y, Yamamura Y, Inoue T, Tanaka T: Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 272: 546-551, 1995
8. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C: Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291: 1963-1971, 2004
9. Chapman AB, Guay-Woodford L, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner J, Wetzel L, Brummer M, O'Neill WC, Robbin M, Bennett WM, Klahr S, Hirschman G, Kimmel P, Thompson PA, Mitler P: Renal structure in early autosomal-dominant polycystic kidney disease: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 64: 1035-1045, 2003